Evidence map›Paper›PMID 40282464›Full record

ArticleCancers2025

Optimizing Cabozantinib Dosing in Unresectable Hepatocellular Carcinoma of 7-on/7-off Regimen.

Yudai Fujiwara, Hidekatsu Kuroda, Tamami Abe, Kei Endo, Takayoshi Oikawa, Mio Tsuruoka, Masashi Ninomiya, Masashi Fujita, Kazumichi Abe, Tomohiro Katsumi and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Yudai FujiwaraDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.ORCID 0009-0000-9569-3273
Hidekatsu KurodaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.ORCID 0000-0002-1471-1087
Tamami AbeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Kei EndoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Takayoshi OikawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.ORCID 0000-0002-1100-6980
Mio TsuruokaDivision of Gastroenterology, Tohoku University Graduate School of Medicine, Miyagi 9808574, Japan.
Masashi NinomiyaDivision of Gastroenterology, Tohoku University Graduate School of Medicine, Miyagi 9808574, Japan.
Masashi FujitaDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 96012950, Japan.
Kazumichi AbeDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 96012950, Japan.
Tomohiro KatsumiDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata 9902311, Japan.ORCID 0000-0001-5670-7505
Shinichiro MinamiDepartment of Gastroenterology, Graduate School of Medicine, Akita University, Akita 0100041, Japan.
Wataru SatoDepartment of Gastroenterology, Graduate School of Medicine, Akita University, Akita 0100041, Japan.
Go IgarashiDepartment of Gastroenterology, Hirosaki University Graduate School of Medicine, Aomori 0368563, Japan.
Chikara IinoDepartment of Gastroenterology, Hirosaki University Graduate School of Medicine, Aomori 0368563, Japan.ORCID 0000-0001-6844-4415
Nobukazu TanabeDepartment of Gastroenterology, National Hospital Organization Sendai Medical Center, Miyagi 9830045, Japan.
Hiroshi NumaoDepartment of Gastroenterology, Aomori Prefectural Central Hospital, Aomori 0300913, Japan.
Osamu KimuraDepartment of Gastroenterology, South Miyagi Medical Center, Miyagi 9891253, Japan.
Ippeki NakayaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Asami ItoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Takuya WatanabeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Kenji YusaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Tomoaki NagasawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.ORCID 0000-0002-4386-3223
Hiroki SatoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Akiko SuzukiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Yuichi YoshidaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Kei SawaraDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Keisuke KakisakaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.ORCID 0000-0001-9627-138X
Akio MiyasakaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.
Hiromasa OhiraDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 96012950, Japan.
Yoshiyuki UenoDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata 9902311, Japan.ORCID 0000-0001-5623-4250
Takayuki MatsumotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 0283695, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cabozantinib (CAB) causes a high incidence of adverse events in unresectable hepatocellular carcinoma (u-HCC) and requires dose adjustments. We evaluated the efficacy and safety of the 7-on/7-off regimen composed of 7 consecutive days' administration of CAB followed by a 7-day rest period. This was a retrospective analysis of 35 patients with u-HCC, who were treated with CAB in a multicenter cohort in Japan from 2020 to 2024. The clinical outcomes of 12 patients treated with the 7-on/7-off regimen and 23 patients treated with daily dosing were compared. There were significant differences in overall survival (12.4 months vs. 6.3 months,

Indexed as

adverse eventsALBI scorecabozantinibhepatocellular carcinomatyrosine kinase inhibitor

Identifiers

PMID40282464
PMCPMC12025779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.